

DT11 Rec'd PCT/TO JUN 18 2002

Please type a plus sign (+) in this box → ☐

Approved for use through 10/31/02. DMS 0031-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**TRANSMITTAL
FORM**

(to be used for all correspondence after initial filing)

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	09/980,717	
	Filing Date	November 7, 2001	
	First Named Inventor	James Anthony GALLAGHER	
	Group Art Unit	To be assigned	
	Examiner Name	To be assigned	
Total Number Of Pages In This Submission	5	Attorney Docket No.	303212000600

ENCLOSURES (check all that apply)

- | | | |
|---|--|---|
| <input type="checkbox"/> Fee Transmittal Form | <input type="checkbox"/> Assignment Papers
(for an Application) | <input type="checkbox"/> After Allowance Communication to Group |
| <input type="checkbox"/> Fee Attached | <input type="checkbox"/> Drawing(s) | <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences |
| <input type="checkbox"/> Amendment / Reply | <input type="checkbox"/> Licensing-related Papers | <input type="checkbox"/> Appeal Communication to Group
(Appeal Notice, Brief, Reply Brief) |
| <input type="checkbox"/> After Final | <input type="checkbox"/> Petition | <input type="checkbox"/> Proprietary Information |
| <input type="checkbox"/> Affidavits/declarations | <input type="checkbox"/> Petition to Convert to a Provisional Application | <input type="checkbox"/> Status Letter |
| <input type="checkbox"/> Extension of Time Request | <input type="checkbox"/> Power of Attorney, Revocation
Change of Correspondence Address | <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Return postcard |
| <input type="checkbox"/> Express Abandonment Request | <input type="checkbox"/> Terminal Disclaimer | |
| <input checked="" type="checkbox"/> Information Disclosure Statement;
PTO form 1449; and 10 references | <input type="checkbox"/> Request for Refund | |
| <input type="checkbox"/> Certified Copy of Priority Document(s) | <input type="checkbox"/> CD, Number of CD(s) _____ | |
| <input type="checkbox"/> Response to Missing Parts/
Incomplete Application | Remarks | |
| <input type="checkbox"/> Response to Missing Parts
under 37 CFR 1.52 or 1.53 | | |

SIGNATURE OF APPLICANT, ATTORNEY OR AGENT

Firm or Individual Name	Kate H. Murashige Registration No. 29,959
Signature	<i>Kate H. Murashige</i>
Date	June 12, 2002

CERTIFICATE OF MAILING BY "FIRST CLASS MAIL"

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on June 13, 2002

Jose Luna
Jose Luna


Burden Hours Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.



Docket No. 30212000600

CERTIFICATE OF MAILING BY "FIRST CLASS MAIL"

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:
Assistant Commissioner for Patents, Washington, D.C. 20231, on June 13, 2002.


Jose Luna

PATENT
RECEIVED
JUL 9 2 2002
TECH CENTER 16012300

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of:

James A. GALLAGHER, et al.

Serial No.: 09/980,717

Filing Date: November 7, 2001

For: A COMPOUND FOR USE IN
MEDICINE

Examiner: To be assigned

Group Art Unit: To be assigned

**INFORMATION DISCLOSURE
STATEMENT UNDER 37 C.F.R. § 1.97**

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

Pursuant to 37 C.F.R. § 1.97 and § 1.98, Applicants submit for consideration in the above-identified application the documents listed on the attached Form PTO-1449. Copies of the documents are also submitted herewith. The Examiner is requested to make these documents of record.

This Information Disclosure Statement is submitted:

- ☐ With the application; accordingly, no fee or separate requirements are required.
- ☒ Within three months of the application filing date or before mailing of a first Office Action on the merits; accordingly, no fee or separate requirements are required.
- ☐ After receipt of a first Office Action on the merits but before mailing of a final Office Action or Notice of Allowance.
 - ☐ A fee is required. A check in the amount of * is enclosed.
 - ☐ A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached to this submission in duplicate.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided below; accordingly; no fee is believed to be due.
- ☐ After mailing of a final Office Action or Notice of Allowance, but before payment of the issue fee.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided below and a check in the amount of * is enclosed.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided below and a Fee Transmittal form (PTO/SB/17) is attached to this submission in duplicate.

Applicants would appreciate the Examiner initialing and returning the Form PTO-1449, indicating that the information has been considered and made of record herein.

The information contained in this Information Disclosure Statement under 37 C.F.R. § 1.97 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal letter is separated from this document and the Patent Office determines that an extension and/or other relief is required, applicant petitions for any required relief including extensions of time and authorizes the Assistant Commissioner to

charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing 303212000600. However, the Assistant Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Dated: June 12, 2002

Respectfully submitted,

By: Kate H. Murashige
Kate H. Murashige
Registration No. 29,959

Morrison & Foerster LLP
3811 Valley Centre Drive
Suite 500
San Diego, California 92130-2332
Telephone: (858) 720-5112
Facsimile: (858) 720-5125

RECEIVED

JUL 02 2002

PTO/SB/08 (2-92)

Sheet 1 of 2

Form PTO-1449	TECH CENTER 1600/2900	Docket Number 303212000600	Application Number 09/980,717
INFORMATION DISCLOSURE CITATION IN AN APPLICATION		Applicant James A. GALLAGHER et al.	
(Use several sheets if necessary)		Filing Date November 7, 2001	Group Art Unit To be assigned
		Mailing Date June 13, 2002	



U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Country	Class	Subclass	Translation YES NO
	1.	09/1998	EP 0 861 666	EP			
	2.	09/1998	WO 98 37764	WIPO			

OTHER DOCUMENTS

(including author, title, Date, Pertinent Pages, Etc.)

Examiner Initials	Ref. No.	Title
	3.	Coulson et al. "Effect of Chlorpropamide on Renal Response to Parathyroid Hormone in Normal Subjects and in Patients with Hypoparathyroidism and Pseudohypoparathyroidism" Journal of Pharmacology and Experimental Therapeutics 194(3):603-613 (1975)
	4.	Davies et al. "Parathyroid Hormone and Adenylate Cyclase" Lancet 1 p.363 (1976)
	5.	Golstein et al. "P-Glycoprotein Inhibition by Glibenclamide and Related Compounds" European Journal of Physiology 437:652-660 (1999)
	6.	Hammon et al. "Interleukin-1 β Secretion Is Impaired by Inhibitors of the Atp Binding Cassette Transporter, ABC1" Blood 90(8):2911-2915 (1997)
	7.	Numann et al. "Altered Action of Parathyroid Hormone by Chloropamide" Surgery 75(6):869-873 (1974)
	8.	Reynolds "Martindale- The Extra Pharmacopoeia" 31st Edition; Royal Pharmaceutical Society; pp.346-348; 360-361 (1996) XP 002151468
	9.	Shigeki et al. "A Case of XX-Male with Osteoporosis and Diabetes Mellitus" Abstract; Database BIOSIS [Online] Biosciences Information Service; Philadelphia, PA; Accession No. PREVI99800178722; XP002149245
	10.	Tomoyoshi et al. "Altered Bone Metabolism in db/db Mice" Abstract; Database BIOSIS [Online] Biosciences Information Service; Philadelphia, PA; Accession No. PREVI99395127739; XP002149246

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.